Inhibition of bone resorption with H.sub.1 -blocking antihistamines

• US 4,256,743 A
• Filed: 10/26/1979
• Issued: 03/17/1981
• Est. Priority Date: 02/22/1979
• Status: Expired due to Term

• Current Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Original Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Inventors: Goldhaber, Paul
• Primary Examiner(s): Robinson, Douglas W.
• Application Number:
  US06/088,397
• Time in Patent Office: 508 Days
• Field of Search: 424/263, 424/246, 424/247, 424/325
• US Class Current: 514/226.2
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/54 having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Abstract

Inhibition of bone resorption in mammals suffering from a disease in which bone resorption exceeds new bone formation by administering an H₁ -blocking antihistamine.

Claims

1. A method for inhibiting bone resorption which comprises administering orally to a mammal suffering from osteoporosis or chronic destructive periodontal disease an H₁ -blocking antihistamine selected from the group consisting of the H₁ -blocking phenothiazines, the H₁ -blocking ethylenediamines, and the H₁ -blocking indenes, the amount being from 25-50 mg/day in the case of said phenothiazines, 25-50 mg up to 4 times a day in the case of said ethylenediamines, 1-2 mg 1 to 3 times a day in the case of said indenes.

2. The method as claimed in claim 1 in which said H₁ -blocking phenothiazine is promethazine hydrochloride, said H₁ -blocking ethylenediamine is selected from the group consisting of tripelennamine hydrochloride and pyrilamine maleate, and said H₁ -blocking indene is dimethindene maleate.

3. The method as claimed in claim 2 in which said disease is osteoporosis and said antihistamine is promethazine hydrochloride.

4. The method as claimed in claim 2 in which said disease is osteoporosis and said antihistamine is tripellenamine hydrochloride.

5. The method as claimed in claim 2 in which said disease is osteoporosis and said antihistamine is pyrilamine maleate.

6. The method as claimed in claim 2 in which said disease is osteoporosis and said antihistamine is dimethindene maleate.

7. The method as claimed in claim 2 in which said disease is periodontitis and said antihistamine is promethazine hydrochloride.

8. The method as claimed in claim 2 in which said disease is periodontitis and said antihistamine is tripellenamine hydrochloride.

9. The method as claimed in claim 2 in which said disease is periodontitis and said antihistamine is pyrilamine maleate.

10. The method as claimed in claim 2 in which said disease is periodontitis and said antihistamine is dimethindene maleate.

11. The method as claimed in claim 1 in which said H₁ -blocking antihistamine is an H₁ -blocking phenothiazine.

12. The method as claimed in claim 1 in which said H₁ -blocking antihistamine is an H₁ -blocking ethylenediamine.

13. The method as claimed in claim 1 in which said H₁ -blocking antihistamine is an H₁ -blocking indene.